empagliflozin

Ligand id: 4754

Name: empagliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 108.61
Molecular weight 450.14
XLogP 2.9
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Natural product or derivative
Approved drug? Yes (source: FDA & EMA (2014))
IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
International Nonproprietary Names
INN number INN
9398 empagliflozin
Synonyms
BI 10773
Database Links
CAS Registry No. 864070-44-0 (source: Scifinder)
ChEBI CHEBI:82720
ChEMBL Ligand CHEMBL2107830
PubChem CID 11949646
Search Google for chemical match using the InChIKey OBWASQILIWPZMG-QZMOQZSNSA-N
Search Google for chemicals with the same backbone OBWASQILIWPZMG
Search PubMed clinical trials empagliflozin
Search PubMed titles empagliflozin
Search PubMed titles/abstracts empagliflozin
Wikipedia Empagliflozin
Comments
Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar.
It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.